1. Home
  2. FAMI vs TCRT Comparison

FAMI vs TCRT Comparison

Compare FAMI & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FAMI
  • TCRT
  • Stock Information
  • Founded
  • FAMI 2015
  • TCRT 1998
  • Country
  • FAMI China
  • TCRT United States
  • Employees
  • FAMI N/A
  • TCRT N/A
  • Industry
  • FAMI Packaged Foods
  • TCRT Biotechnology: Pharmaceutical Preparations
  • Sector
  • FAMI Consumer Staples
  • TCRT Health Care
  • Exchange
  • FAMI Nasdaq
  • TCRT Nasdaq
  • Market Cap
  • FAMI 3.4M
  • TCRT 3.8M
  • IPO Year
  • FAMI 2018
  • TCRT N/A
  • Fundamental
  • Price
  • FAMI $0.28
  • TCRT $2.39
  • Analyst Decision
  • FAMI
  • TCRT
  • Analyst Count
  • FAMI 0
  • TCRT 0
  • Target Price
  • FAMI N/A
  • TCRT N/A
  • AVG Volume (30 Days)
  • FAMI 544.2K
  • TCRT 15.9K
  • Earning Date
  • FAMI 11-29-2024
  • TCRT 11-14-2024
  • Dividend Yield
  • FAMI N/A
  • TCRT N/A
  • EPS Growth
  • FAMI N/A
  • TCRT N/A
  • EPS
  • FAMI 0.13
  • TCRT N/A
  • Revenue
  • FAMI $86,261,500.00
  • TCRT $7,000.00
  • Revenue This Year
  • FAMI N/A
  • TCRT N/A
  • Revenue Next Year
  • FAMI N/A
  • TCRT N/A
  • P/E Ratio
  • FAMI $2.28
  • TCRT N/A
  • Revenue Growth
  • FAMI N/A
  • TCRT N/A
  • 52 Week Low
  • FAMI $0.17
  • TCRT $1.95
  • 52 Week High
  • FAMI $2.35
  • TCRT $33.00
  • Technical
  • Relative Strength Index (RSI)
  • FAMI 46.10
  • TCRT 54.94
  • Support Level
  • FAMI $0.28
  • TCRT $2.07
  • Resistance Level
  • FAMI $0.32
  • TCRT $2.38
  • Average True Range (ATR)
  • FAMI 0.03
  • TCRT 0.21
  • MACD
  • FAMI -0.00
  • TCRT 0.04
  • Stochastic Oscillator
  • FAMI 44.44
  • TCRT 48.35

About FAMI Farmmi Inc.

Farmmi Inc is a supplier of agricultural products. The products of the company are Shiitake Mushroom, Mu Er Mushroom and other edible fungi and other agricultural products. The majority of products are sold in mainland China.

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.

Share on Social Networks: